Cervical dystonia — improving the effectiveness of botulinum toxin therapy

Małgorzata Tyślerowicz¹, Weronika Kiedrzyńska¹, Bożena Adamkiewicz¹, Wolfgang H. Jost², Jarosław Sławek³

¹Department of Neurology, Copernicus Memorial Hospital in Łódz, Comprehensive Cancer Centre and Traumatology, Łódz, Poland
²Parkinson-Klinik Ortenau, Wolfach, Germany
³Department of Neurological-Psychiatric Nursing, Medical University of Gdańsk, Poland; Department of Neurology, St Adalbert Hospital, Copernicus Ltd, Gdańsk, Poland

ABSTRACT

Introduction. Cervical dystonia is the most frequent form of focal dystonia. It is characterised by involuntary muscular contractions resulting in abnormal head/neck and shoulder movements and postures, which can be associated with tremor and pain. Local intramuscular injections of botulinum toxin type A (BoNT-A) is the treatment of choice, being both effective and well-tolerated. However, a considerable number (c. 30%) of patients discontinue this treatment.

The aim of this review was to analyse the factors possibly responsible for treatment failures of cervical dystonia (CD), with special regard to the new classification known as the ‘Col-Cap’ concept and non-motor symptoms.

Clinical implications. Several factors analysed in this review are responsible for effective treatment: proper diagnosis of dystonia and exclusion of pseudodystonias, correct recognition of dystonia pattern and identification of new patterns according to the Col-Cap concept, muscle selection and precise injections under electromyography (EMG) and/or ultrasonography (US) guidance. Furthermore, concomitant diagnosis and treatment of non-motor symptoms such as depression, anxiety, fatigue, sleep problems, phobias and stigmatisation are crucial in obtaining the best overall effect of the treatment. Primary and secondary immunisation and non-responsiveness seem to be marginal problems nowadays due to a low potential of new BoNT-A formulations to produce neutralising antibodies.

Future directions. There is a need for new and relevant scales combining the Col-Cap concept patterns with non-motor symptoms and quality of life. There is also a lack of specific rehabilitation protocols which could enhance BoNT-A treatment results.

Key words: cervical dystonia, Col-Cap concept, botulinum toxin, treatment failures, primary non-responsiveness, secondary non-responsiveness

Introduction

Cervical dystonia (CD) is a movement disorder characterised by involuntary, sustained or intermittent muscle contractions leading to abnormal head movements and/or positioning. It is accompanied by pain in 67–75% of patients [1]. Typical features include sensory trick and head tremors. A substantial number of patients (18–41%) demonstrate complications manifesting in premature degenerative disorder of the cervical spine, discopathy or cervical myelopathy [2]. CD significantly reduces quality of life, affects the ability to work, and socially stigmatises patients [2–3]. Spontaneous remission occurs in up to 15% of patients and is usually temporal [5, 6], but may be triggered by botulinum neurotoxin type A (BoNT-A) treatment [4]. CD is the most common focal dystonia: a meta-analysis reveals that it affects a mean 4.98 of every 100,000 people. However, a significant difference has been observed with regards to geographical location: in Japan the rate is 2.52, whereas in Europe it is 6.71 [5].

Address for correspondence: Małgorzata Tyślerowicz, Neurology and Neurophysiology Department, Copernicus Memorial Hospital in Łódz, Comprehensive Cancer Centre and Traumatology, Łódz, Poland, e-mail: mtyslerowicz@wp.pl
Avoid fatal progression and outcome like e.g. Wilson's disease. However, the latter may require specific treatment to condition the central mechanism of non-specific muscle activation.

Table 1. Summary of possible causes of non-responsiveness or unsatisfactory effect of Botulinum toxin type A treatment of cervical dystonia

1. Primary non-responsiveness
   - preexisting BoNT-A antibodies, chronic exposure to BoNT-A in childhood, cross-reaction of other antibodies (e.g. tetanus toxoid)
2. Secondary non-responsiveness
   - neutralizing antibodies
   - change in the pattern of dystonia, conditioned by the central mechanism of non-specific muscle activation
3. Misdiagnosis
   - dystonia in neurodegenerative diseases (PSP — usually retrocollis, MSA — usually anterocollis)
   - genetic disorders: Wilson's disease, Huntington's disease, spinocerebellar ataxias, neuroacanthocytosis, NBIA
   - dystonia in mitochondrial disorders
   - secondary dystonia caused by identified factors: post-traumatic dystonia, post-stroke dystonia, post-inflammatory dystonia, tardive dystonia, toxin-related dystonia
   - functional dystonia (psychogenic)
   - pseudodystonias:
     a. related to musculoskeletal deformations: camptocormia, scoliosis, Grisel's syndrome, Arnold-Chiari syndrome, Klippel-Feil syndrome, joints deformities, arthrogryposis, Dupuytren's contracture, congenital muscular torticollis, Sandifer's syndrome,
     b. related to the compensation of improper functioning of the central nervous system or peripheral nervous system (compensatory head tilt): vestibular system disorder, oculomotor nerves palsies (6th, 4th), mass lesion in the posterior fossa
     c. disorders of sensory pathways: parietal lobe damage, syringomyelia, myelopathy, mono- and polyneuropathy
     d. disorders of motor pathways: Isaac's syndrome, stiff-person syndrome, tetanus, myotonic disorders, MMN
4. Misidentification of the subtype of dystonia (new classification — according Col-Cap concept and new CD patterns with involvement of muscles not routinely injected earlier)
5. Improper selection of active muscles (injections of muscles that are not responsible for specific pattern) and missing the muscles (no guidance, too short needles, too deep injections missing thin muscle layers, e.g. m. trapezius)
6. Lack of monitoring techniques of injections: us, emg (combination is the optimal method as visualization does not mean that muscle is really active)
7. Improper adjustment of the total dose and its distribution in particular muscles
8. Subjective feeling of lack of improvement (dominating non motor symptoms like depression, anxiety, phobias or sleep problems)
9. Long-lasting dystonias causing secondary changes like myofibrosis, contractures
10. Improper storage and transportation of the medication

Treatment of CD with BoNT-A is the treatment of choice as recommended by the American Academy of Neurology (AAN), with high effectiveness and safety profiles [6].

Double-blind, randomised clinical, as well as open, studies have shown that 50–85% of patients demonstrate a significant improvement [7–15]. A considerable number (c. 30%, range 19–46%) of patients discontinue treatment once it appears to be ineffective [16–20]. Treatment may be considered ineffective if neither the patient nor the therapist have observed a satisfactory reduction of symptoms or if significant adverse effects occur (e.g. dysphagia or neck muscles weakness), or when clinical trials observe no significant score reduction in rating scales. Those most commonly used are the Tsui Scale and the Toronto Western Spasmodic Torticollis Rating Scale, TWSTRS.

This article aims to analyse the possible factors responsible for treatment failures, with special regard to the new classification of CD known as the Col-Cap concept and non-motor symptoms.

Making a proper diagnosis

BoNT-A can be effective both in primary and secondary dystonia. However, the latter may require specific treatment to avoid fatal progression and outcome like e.g. Wilson's disease. Therefore, a proper diagnosis is essential. Particular attention should be paid to pseudodystonias that mimic dystonia and do not respond to treatment. Revised definitions and an extended list of pseudodystonic postures was recently presented by Berlot et al. (Tab. 1) [21]. Pseudodystonic postures must be clearly differentiated from conditions related to muscles weakness which can result in a head-drop e.g. myasthenia, muscular dystrophy, and amyotrophic lateral sclerosis. Moreover, pathological anteflexion can be confusing (e.g. anteflexion in multiple system atrophy) because there is no consensus as to whether it is related to dystonia of flexors or myositis and weakness of neck extensors [22]. It has been speculated that neck extensor myopathy might follow mechanical over-stretching from flexor dystonia. There is evidence that even muscles which are not under mechanical stress can develop myopathic changes. Pathologic changes seen in inflammatory myopathies (IBM) have been found in clinically affected paraspinal muscles. This shows the neurodegenerative nature of both IBM and parkinsonism.

Additionally, functional CD may be refractory to BoNT-A treatment. It usually presents as fixed dystonia or is multidirectional, variable with different patterns at the same time, accompanied by enormous effort put into head positioning, with improvement after distraction, and no sensory twitches.
**Proper identification of dystonia pattern**

One of the most common reasons behind therapy failures seems to be incorrect identification of the clinical pattern of CD. To properly identify the subtype of dystonia, the patient should be examined carefully, not only in a relaxed seated position when their upper body is in a resting state, but also with open and closed eyes (because closing eyes can worsen dystonic posture), standing and/or lying positions, while walking or performing activities such as writing (these can enhance dystonic movements).

By observing the patient from the side, the front, and also from the back, we can assess the change in head and neck position in each of the three planes. Sometimes an objective assessment may be difficult due to the activity of compensating muscles as well as coexistence of tremors and/or myoclonus. We should pay attention to the so-called ‘sensory twitches’ (as they may change the pattern temporarily), shoulder and scapula positions, and potential muscle hypertrophy and pain. If the arm is elevated, we should assess the patient by stabilising their arms by pushing down the elevated arm. This may reveal its compensating character to maintain the head erect position due to a severe head tilt.

The Col-Cap concept was first set out by Reichel et al. in 2009 [23]. Their careful examination identified new patterns not previously recognised. Initially, CD had been classified into four types. These related to: turning the head (torticollis), tilting the head to one side (laterocollis), backwards (rerocolliis), or forwards (anterocollis). More than 50% of cases were diagnosed as torticollis, 10–15% as laterocollis or rerocolliis, and less frequently anterocollis [24]. The ‘Col-Cap’ concept (collum-caput = neck-head) was invented on the basis of imaging examinations (CT/MRI of the head, cervical spine and also soft tissues) and functional anatomy. According to this approach, based on the various movements of the head (muscles insertions between skull and C2 spine level) and neck (muscles insertions between C2 and C7 level), 10 major subtypes of CD were identified (Fig. 1): transverse (torticollis/collis), frontal (laterocollis/collis), sagittal with tilting forwards (anterocollis/collis) or backwards (rerocolliis/collis) [25, 26]. These distinctive patterns are ‘realised’ by the activity of different (i.e. different from those in the ‘classic four’) muscles involved in the particular type. So an inaccurate diagnosis may result in a lack of effect. According to the multicentre study recently published by Jost et al. analysing 306 consecutive patients with CD, pure forms are rare (16.3%), whereas combinations of 2–6 of the subtypes are common (83.7%). Among all the subtypes, the most common primary form is anterocollis (49%), and the second most common is laterocollis (16.7%) [27]. One can also distinguish combinations of incorrect positions such as a mixture of laterocollis to one side and laterocaput in the opposite direction; this is known as lateral shift. In addition, we see a combination of anterocollis and retrocaput called anterior sagittal shift, and consequently posterior sagittal shift as a combination of retrocollis and anterocaput.

To identify these new patterns, characteristic points/lines should be identified, which enables levels of movement (collis, caput) to be distinguished. In the case of torsion, the main anatomical structures are: superior thyroid incisure of the larynx and manubrium of the sternum above the jugular incisure. Rotational torticollis is diagnosed if, during rotation, the larynx shifts in relation to the sternum. If these points remain in the same line, but the chin shifts in relation to the larynx, rotational head position is diagnosed (torticollis). In the sagittal plane, the meatus acusticus externus and the clavicles are useful anatomical landmarks. If only the ‘head’ is concerned, the meatus acusticus stays in line with the clavicles (anterocaput, retrocaput). If the projection is in front or behind the clavicles, the ‘neck’ level is involved (anterocollis/anterocaput) (Fig. 1) [28]. A treatment protocol differentiating the head and the neck level may result in better outcomes. However, to date this has only been shown in one retrospective study [29].

Based on the Col-Cap concept, ‘main’ muscles should be injected as the first choice, then ‘secondary’ in each subtype. In complex patterns, the leading (or primary) one should be first injected and in refractory cases previous injection patterns should be assessed and modified in the subsequent cycle [29].

**Correct selection of active muscles and guided injections (US/EMG)**

Before the Col-Cap concept, muscles were selected on the basis of functional anatomy; a physical examination accompanied by assessment of muscle hypertrophy, location of pain, or arm elevation. Several published studies used electromyography (EMG) as an injection technique for the identification and localisation of muscles [30–34]. There are studies which strongly support the role of EMG showing that injections performed only according to anatomical landmarks can be imprecise (83% reached the sternocleidomastoid, but only 47% the levator scapula muscle) [35]. Moreover, EMG guidance increases the sensitivity and specificity of the muscle selection, even when performed by BoNT-A specialists. Clinical predictions of individual muscle involvement are only 59% sensitive and 75% specific without EMG use. It has been pointed out that muscular hypertrophy or shoulder elevation indicates ‘dystonic’ muscle activity in only 70% of patients, showing how a classical physical examination can be confusing [36].

The role of EMG has been supported by randomised, blinded studies which have demonstrated that EMG-guided injections vs. anatomically-based bring significantly better results, measured by rating scales and subjective assessment: 82% (TWSTRS) and 61% (patients assessment) vs. 8% (TWSTRS) and 25% (patient report) respectively [34]. The same was proved in another study, which showed a significant difference in Jankovic scale (p = 0.05) between guided and blinded injections [37]. Retrospective analysis confirmed the benefits of
using polymyography in groups of patients previously treated with BoNT with an unsatisfactory response. After one year of treatment, reasonable or good final results were obtained in 60% of patients measured on both the Tsui Scale (p < 0.01) and the subjective assessment of patients (p < 0.001) [38]. Subsequently, one small open trial showed that EMG improved the treatment outcome in 9/10 patients, demonstrating a significant improvement in TWSTRS (mean improvement of 64%) [39]. In contrast, there are studies which do not confirm the utility of EMG guided injections. In a systematic review by Nijmeijer et al., the average improvement on the Tsui Scale was greater (31.9 vs. 43.7%) in studies that used only clinical evaluation [40]. But because of profound differences in methodology, dosage, patient characteristics, and primary and secondary endpoints, no statistical analysis could be performed, and no firm conclusions could be drawn.

To sum up, a consensus of experts recommends a combination of clinical assessment and EMG examination as well

---

**Figure 1.** Ten basic clinical patterns of cervical dystonia according to col-cap concept. **A.** Laterocollis, **B.** Laterocaput, **C.** Lateral shift (combination of laterocollis to one and laterocaput to opposite side), **D.** Torticollis, **E.** Torticaput, **F.** Anterocollis, **G.** Anterocaput, **H.** Sagittal-anterior shift (combination of anterocollis and retrocaput), **I.** Retrocollis, **J.** Retrocaput. Additional rare variant may be present (no picture) presenting as Sagittal posterior shift (combination of retrocollis and anterocaput). Courtesy of Via Medica and Jarosław Sławecki Monika Rudzińska eds, In: Toksyna botulinowa w praktyce neurologicznej, Via Medica, Gdańsk 2015, vol. 1, Fig. 2
as EMG-guided injections in patients treated for the first time (Level A) [34, 41]. But for those who have undergone unsuccessful treatment, EMG usefulness is less proven (Class III studies and Level C) [42, 43].

We must remember that EMG use does not allow us to distinguish between ‘dystonic’ and compensatory muscle activities or to visualise the tip of the needle (the injector is not sure if the needle is positioned in the intended muscle). Such precise targeting of muscles can be achieved using other methods such as ultrasonography (US) or computed tomography (CT).

Ultrasound is an easily available, non-invasive method enabling the visualisation of muscles and surrounding structures (nerve bundles and large vessels) in real time, which may increase the accuracy of injections of not only deep, but also superficial muscles (sometimes as superficial as for example very flat trapezius) muscles. Studies regarding spasticity treatment with BoNT under US guidance have shown its efficacy in localising especially deep muscles. Recent publications are open studies conducted in small groups of patients or case studies on injections of deeply located muscles where the approach is challenging, such as the longus colli muscle or obliquus capitis inferior [41–44]. One of these studies assessed the impact of monitoring techniques such as US and/or CT in a group of eight patients requiring injections in deep cervical muscles (the obliquus capitis inferior, the longus colli muscle, obliquus capitis superior, scalenus anterior and scalenus posterior). The Tsui Scale confirmed a significant improvement occurring within four weeks (11.75 vs. 1.50) and on the TWSTRS scale in each of the subscales (20.0 vs. 5.25, 20.0 vs. 7.00, and 13.10 vs. 6.50) [48]. A study conducted in a group of five patients to assess the incidence of swallowing problems after injections revealed that an ultrasound examination, carried out in order to locate the EMG needle during injections in the sternocleidomastoid, significantly reduced such adverse effects (0% vs. 34.7%) [45]. Nevertheless, no randomised, controlled studies have proved the greater effectiveness of US-guided versus blinded injections.

Muscles which seem to ‘benefit’ mostly from US monitoring include: suprahyoid muscles, scalenus muscles, the longissimus capitis and cervicis, semispinalis capitis and cervicis, obliquus capitis inferior (crucial muscles in some col-cap patterns), but also the sternocleidomastoid, levator scapulae, and trapezius (frequently injected too deeply) [46].

It seems that in some cases, particularly with accompanying tremors or after several non-effective treatment attempts, EMG and US methods, applied simultaneously, should be considered [47]. The needle size should also be adjusted because one that is too short will not reach deep muscle layers, although these can be easily detected thanks to US guidance.

**Optimal dosage and its distribution in particular muscles**

The optimal dose of BoNT-A was obtained in pivotal studies. The recommendations according to SPC (summary product characteristics) are based on these clinical studies. However, dosage should be adjusted in subsequent treatment cycles both in terms of effectiveness and safety. There are studies which indicate that efficacy and the incidence of side effects depend on the BoNT-A dose. A study assessing abobotulinumtoxin A showed that the largest and longest improvements were obtained in the 1,000U group [12]. Nevertheless, the highest number of adverse events also occurred in this group. All groups (placebo, 250U, 500U and 1,000U) demonstrated improvements > 20% on the Tsui Scale after two weeks. However, in week 4 such improvements were still observed only in the 500 U and the 1,000 U groups. In these groups, also compared to the 250U and placebo groups, patients reported > 50% improvement on CGI scale statistically more frequently. Therefore, the experts’ recommendations, based on those studies [12, 48], suggest starting treatment by administering 500 U of abobotulinumtoxin. However, lower (200–400 U) doses might be equally effective and safe if precisely administered e.g. under EMG guidance [49]. In clinical practice, the dose should be adjusted to muscle bulk and body mass, although formal studies have not been performed.

There are no randomised, controlled studies comparing the effectiveness of the number of injections per muscle. A comparative study on 49 patients showed that multi-point injections increased treatment effectiveness: they reduced pain (p < 0.002), increased the range of motion (p < 0.001), and lengthened the duration of effect (p < 0.001) [50]. Experts recommend distributing the dose to 1–4 points, depending on the area of the muscle [51].

**Subjective feelings of lack of improvement and non-motor symptoms**

Patients suffering from cervical dystonia, like those with other movement disorders, present a wide spectrum of non-motor symptoms which have not been considered in clinical trials assessing BoNT-A effectiveness, but may influence the overall result of therapy.

Patients with CD appear to be more aware of having abnormal dyskinetic movements than do patients with Huntington’s or Parkinson’s Diseases [52]. Non-motor symptoms have been noted in several studies: 61.8% of patients with CD presented lack of self-confidence due to stigmatisation, 59.8% had sleep problems, and 51% fatigue [53]. Depression was prevalent in as many as 47.5% of patients and this was the major determinant of poor quality of life [3]. In another study, poor quality of life was more common in CD than in blepharospasm and writer’s cramp and also depression and anxiety were the major correlates [54]. Depression, along with other emotional-psychological disorders, may constitute a clinical spectrum of CD independently of motor symptoms. Mood disturbances coupled with anxiety, also adjustment disorders or obsessive-compulsive behaviours, occur significantly more often in patients with focal dystonias.
Primary and secondary immuno-resistance

Patients who do not respond to the therapy can be classified as those who did not respond at all from the beginning (so-called primary non-responders, PNR), or those who stopped responding to the treatment after a good initial effect (so-called secondary non-responders, SNR).

It is suspected that primary resistance may be associated with preexisting BoNT-A antibodies (AB), chronic exposure to BoNT-A in childhood, or cross-reaction of other AB (tetanus toxin AB) [63, 64]. However, this is only speculation unsupported by studies. Secondary non-responsiveness is defined differently by different authors. Some authors claim that two consecutive ineffective treatment cycles (i.e. no subjective improvement or exacerbation by at least 2 points on the Tsui Scale as well as absence of side effects typical for BoNT-A) which occur after at least two effective cycles in the past (defined as improvement on the Tsui Scale by at least 3 points and/or atrophy in injected muscles and/or an occurrence of side effects typical for BoNT-A) are enough to diagnose secondary resistance [18]. Others believe that secondary resistance can be diagnosed only after three consecutive ineffective treatment cycles [65]. One should remember that it may be a pseudo-immuno-resistance due to other reasons mentioned earlier, and that the real one should be confirmed in laboratory or clinical tests (see below).

It is estimated that secondary resistance affects approximately 3–5% of patients [66]. Previously the production of AB to BoNT-A was considered the main cause of secondary treatment failure (STF). Some publications indicate that higher BoNT-A doses, administered at shorter intervals and frequent injections (within six weeks of the previous injection, so called booster injections), increase this risk of development of AB [67, 68]. Most of the previous studies reporting AB in groups of CD patients were unbiased regarding STF and had a short duration. Therefore, AB rates reported in these studies more or less represent the incidence of AB induction during 1–2 years of therapy and the range is between 0.5% and 2.0% [69–71]. In long-term treated patients with CD, the prevalence of AB is higher, indicating 14% in the group of patients still responding to therapy who underwent BoNT-A injections over 10 years [72]. Another study showed that duration of treatment of ~15 years carries a risk of up to 40% of becoming AB positive, not influencing the treatment result. In addition, the study showed that single dose per session and BoNT-A formulation were the most significant factors influencing AB formation [73].

Furthermore, the amount of complexing proteins, which differs in the three most commonly used preparations, plays an essential role. Antibodies were found in 9.5% of patients treated only with original onabotulinumtoxinA with a large amount of complexing proteins (100 U/25 ng protein), whereas AB were not detected in any patients treated exclusively with the new preparation of onabotulinumtoxinA (100U/5 ng protein) marketed more than 20 years ago [74]. Antibodies were not found in patients treated with incobotulinumtoxinA, which does not contain complexing proteins [75, 76].

Neutralising antibody titre decreases after discontinuation of therapy. The rate of decline differs for each individual, and
the decline can last for up to four years. Minimum 12-week intervals between injections are still advisable. However, some studies on incobotulinumtoxinA reveal that shorter intervals are also safe and do not produce antibodies [19].

In summary, studies show that AB and their titre do not necessarily contribute to secondary resistance; subsequent studies revealed that antibodies are found in approximately 50% of patients with secondary resistance [77, 78] and the reasons for this situation possibly differ.

According to some studies, secondary resistance could be associated with a higher dose of BoNT-A, administration of other therapies (rehabilitation, pharmaceutical treatment), a significant number of side effects, and more frequent interruptions in BoNT-A treatment [79].

The lack of response due to the neutralising antibodies formation may be diagnosed with specific tests. MPA (mouse protection assay), HDA (hemidiaphragm assay (HDA), and new enzyme-linked immunosorbent assay (ELISA) are currently available. According to the latest reports, a combination of ELISA and HDA is a quick method characterised by the highest sensitivity and its price is reasonable. For 100% sensitivity its specificity is 90%, and for 100% specificity its sensitivity is 55%. Sensitivity of previously used tests, such as MPA or WBA (western blot assay) was lower and ranged from 33% to 53% [80].

Instead of laboratory tests, in clinical practice we can use simple, objective tests involving a unilateral application of BoNT-A in the frontal muscle [74] or in the extensor digitorum brevis muscle. The frontal test is performed by administering 30 units of abobotulinumtoxinA or 10 units of ona/incobotulinumtoxinA [71] in the frontalis muscle on one side. Clinical assessment (ability to raise eyebrows) is recommended after 2–4 weeks. Asymmetry indicates that BoNT-A is effective [43]. For an extensor digitorum brevis muscle test we administer 100 U of abo- or 20 units of ona-botulinumtoxinA in this muscle and assess the compound muscle action potential response (CMAP) by stimulating the peroneal nerve at baseline and two weeks after injection (CMAP should more than halve compared to its original value). For a decline of up to 20%, immunoresistance is quite probable; for values of 20–50%, the result is doubtful [81].

In patients with immunoresistance, we can discontinue injections for 12–18 months and observe the patient at regular intervals. If dystonia significantly reduces quality of life, an alternative is re-administration of BoNT-A. Or one may consider the use of botulinum toxin B, which is safe and effective in the treatment of cervical dystonia, but presents high immunogenicity potential, in particular in patients already resistant to BoNT-A treatment [82, 83].

**Intrinsic muscle changes and change of dystonia pattern**

Muscle fibrosis and contractures, being the result of long-lasting disease as well as a change in the pattern of dystonia, play an important role in secondary resistance apart from immunisation. The muscular dystonia pattern may change in some patients over time. BoNT-A injections may ‘activate’ other previously inactive muscles (contributing to the similar clinical pattern of dystonia), which implies the activity of a central mechanism, conditioning the position of the head or neck through non-specific muscle activation. The clinical pattern of dystonia in the course of the disease can also change. This probably results from activation of other muscles, which in turn results from a peripheral block of initially active dystonic muscles, or a change of the activation centre at the level of the central nervous system [84–86].

**Evaluating the effectiveness of treatment**

A lack of improvement in a patient’s assessment may contradict the positive change in rating scales. The most commonly used are Tsui, CIDP-58 and TWSTRS.

The TWSTRS is most commonly used in clinical trials and serves as the primary endpoint for assessing the effectiveness of BoNT-A in treating CD [14, 17, 87–90]. In most studies, an improvement by 25–30% measured with this scale is considered significant. It shows a strong correlation with the Tsui Scale [91]. Despite many advantages however, it does not take into account the evaluation of dystonic tremor; there is no clear definition of the midline and the full range of motion [92]. This scale also cannot assess properly the complex patterns of CD demonstrated in the Col-Cap concept.

In addition, due to its complex nature, the scale can hardly ever be applied in everyday practice. The authors of one recent study determined the number of points in the TWSTRS scale which contributes to a minimally clinically perceptible change in the Patient Global Impression of Change (PGIC) scale: a change by 3 points in milder cases (≤ 28.5) and 18 points in severe cases (> 52) [93]. A linear relationship was also found between the TWSTRS total scores and the PGIC: an improvement by 2.9 points in the PGIC scale corresponded to improvement by 25–30% measured with this scale is considered significant. It shows a strong correlation with the Tsui Scale [91]. Despite many advantages however, it does not take into account the evaluation of dystonic tremor; there is no clear definition of the midline and the full range of motion [92].

The lack of a specified rating scale including both motor (with respect to the new Col-Cap patterns) and wide spectrum of non-motor CD features seems to be an unmet need. Moreover, it may create difficulties when planning new studies [94].

The next unmet need is the lack of consensus on specific rehabilitation programmes dedicated to CD patients and aimed at enhancing the effect of BoNT-A therapy.

In conclusion, CD treatment with BoNT-A remains a challenge for the physician. It is rare to obtain satisfactory effects at the first session. If unsuccessful, the long list of possible reasons, which have been the subject of this paper, should be considered.

**Conflicts of interest:** All authors declare no conflict of interest

**Funding:** No funding sources
**Ethical committee permission:** Not necessary as this paper is a review, with no participation by patients or animals and no experiments

**Acknowledgements:** None

**References:**


